Business Wire

Arthur D. Little: New Report Offers a Blueprint for Overcoming Bottlenecks and Unlocking the Full Potential of Digitalisation in the Chemical Industry

19.4.2023 10:51:00 EEST | Business Wire | Press release

Share

Digitalisation has the power to transform the European chemical industry, revolutionising the sector's solutions and enabling a circular, more sustainable economy in line with the EU Green Deal objectives. This exciting potential is highlighted in a new report from Arthur D. Little and Cefic, the European Chemical Industry Council, which details how technologies like artificial intelligence, big data, Internet of Things, digital twins, robotics, virtual/augmented reality, and blockchain can accelerate the industry's transformation.

The study titled "Digital Technologies for Sustainability in the European Chemical Industry", is the first ever attempt to outline how these technologies are used in the chemical sector and how they can be scaled up to make the chemical industry’s processes and products more sustainable .

Dr. Daniel Witthaut, Executive Director for Innovation at Cefic, emphasises that while the EU chemical industry has already implemented digitalisation in various applications, there is still much more that can be done:

“Digitalisation in the chemical industry is not new with multiple players already applying digital technologies in their fields. However, enormous opportunities exist for the industry to reach their sustainability goals faster through the application of the latest digital technologies – a journey that is just beginning for most players. And this is where we also need to work more closely with EU institutions to remove existing bottlenecks, improve data sharing and create a larger pool of homegrown talent to implement all these new technologies”.

According to the research, digital technologies can make the greatest contribution in five priority areas in both large and small companies in the EU: (1) process design and production for climate and circularity objectives, (2) sustainability assessment, (3) enabling materials and chemicals circularity through tracking and tracing, (4) sustainable product design, and (5) safe and efficient logistics and distribution.

Dr. Michaël Kolk, Managing Partner at ADL, adds: “Chemical companies in Europe are not only working on their own sustainability objectives, but also providing solutions that serve as enablers for many downstream industries to reach their own. The picture is complex, but we believe that collaboration via greater digitalisation is the way forward.”

The report also highlights a number of challenges that must be addressed to fully realise the potential of digital technologies. These include technological challenges such as data availability, interoperability, standardisation and cybersecurity as well as reluctance among companies to share data, financial costs, organisational issues, and a shortage of digital skills in the workforce. Greater collaboration between EU institutions and the chemical industry will be needed to address some of these bottlenecks.

The report is available for download here: https://tinyurl.com/2s4bztsb

END

About the report

Arthur D. Little and the European Chemical Industry Council (Cefic) joined forces to prepare this report, which summarises the views of digital technology experts from within and outside the chemical industry.

Recommendations from this report are based on the result of 15 individual interviews with senior digital and sustainability experts (e.g., chief digital officers or chief sustainability officers) as well as a survey of more than 70 experts from 50 companies that are broad representatives of the chemical industry in terms of type of business, size, and region.

To add cross-industry perspectives, the study also took into account input from more than 10 globally recognised digital technology experts outside the chemical industry.

About Cefic

Cefic, the European Chemical Industry Council, founded in 1972, is the voice of large, medium and small chemical companies across Europe, which provide 1.2 million jobs and account for approximately about 15% of world chemicals production.

About Arthur D. Little

Arthur D. Little has been at the forefront of innovation since 1886. We are an acknowledged thought leader in linking strategy, innovation and transformation in technology-intensive and converging industries. We navigate our clients through changing business ecosystems to uncover new growth opportunities. We enable our clients to build innovation capabilities and transform their organizations.

Our consultants have strong practical industry experience combined with excellent knowledge of key trends and dynamics. ADL is present in the most important business centers around the world. We are proud to serve most of the Fortune 1000 companies, in addition to other leading firms and public sector organizations.

For further information, please visit www.adlittle.com or www.adl.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media contact: Marina Mendes
Cefic
+32 499239522
mam@cefic.be

Media contact: Sue Glanville
Catalyst Comms
+44 7715 817589
Glanville.sue@adlittle.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release

The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 12:52:00 EEST | Press release

The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not merely a wage dispute. It stems from deep structural concerns regarding the company’s ESG management, lack of operational autonomy, and passive labor relations. Primarily, the union highlighted unresolved corporate governance issues, including allegations concerning unfair labor practices and the unauthorized use of employee personal data, which were prominently reported by South Korea's major broadcaster, MBC, in November 2025. The union believes this crisis stems from management's failure to address r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye